INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast Cancer

NCT ID: NCT04781725

Last Updated: 2021-11-17

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 90 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-03-25
• Study Completion Date: 2023-03-01

Brief Summary

This is a phase II, randomized, multi-center, parallel design, window of opportunity trial evaluating intratumoral INT230-6 in up to 90 patients with early stage breast cancer. In a 2:1 randomization, patients on the treatment arm will receive intratumoral INT230-6 injections prior to breast surgery.

Detailed Description

The study comprises 2 consecutive parts. The first part will be to test safety and feasibility of the dosing procedures. Results from Part I of the study will standardise the optimal dose and frequency of INT230-6 for participants in Part II.

Part I: Open-label 2:1 randomized study of up to 30 patients. Treatment arm patients will be given up to 3 doses of INT230-6 injected weekly prior to breast surgery, at a dose based on longest diameter. The control arm patients receive no treatment.

Part II: Double-blind, 2:1 randomized study of up to an additional 60 patients. The placebo arm includes a saline injection of similar dose and frequency as the treatment arm (up to 2 doses of INT230-6/saline injected weekly prior to breast surgery).

Conditions

Breast Cancer

Keywords

window of opportunity; intratumoral; Ki67; complete pathologic response (PCR); immune activation; INT230-6; cisplatin; vinblastine; cell cycle arrest

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

INT230-6 Treated Arm

Part I: Patients will receive up to 3 doses of INT230-6 injected weekly prior to breast surgery

Part II: Patients will receive up to 2 intratumoral doses of INT230-6 (over a 15-day period) prior to breast surgery

Group Type: EXPERIMENTAL

INT230-6

Intervention Type: DRUG

INT230-6 is a formulation of two well known chemotherapeutic agents, cisplatin (0.5mg/mL) and vinblastine sulfate (0.1mg/mL), combined with 2-hydroxybenzoylaminooctanoate (also known as SHAO-FA or SHAO as a sodium salt at 10mg/mL).

Saline injection

Intervention Type: OTHER

Standard 0.9 % NaCl Normal Saline

Control Arm

Part I: No intervention while awaiting surgery

Part II: Placebo saline injection

Group Type: PLACEBO_COMPARATOR

Saline injection

Intervention Type: OTHER

Standard 0.9 % NaCl Normal Saline

Interventions

INT230-6

INT230-6 is a formulation of two well known chemotherapeutic agents, cisplatin (0.5mg/mL) and vinblastine sulfate (0.1mg/mL), combined with 2-hydroxybenzoylaminooctanoate (also known as SHAO-FA or SHAO as a sodium salt at 10mg/mL).

Intervention Type: DRUG

Saline injection

Standard 0.9 % NaCl Normal Saline

Intervention Type: OTHER

Other Intervention Names

Cisplatin; Vinblastine; 2-hydroxybenzoylaminooctanoate (SAHO)

Eligibility Criteria

Inclusion Criteria

1. Female patients with newly diagnosed histologically confirmed primary invasive breast cancer currently not undergoing any treatment while awaiting surgery.

2. Patients with early, operable stage I to II breast cancer amendable for complete surgical resection as assessed by treating surgical oncologist.

3. Tumors must be clinically palpable by surgeon. Part I: ≥ 1.0 cm by palpation or on imaging. Part II: ≥ 1.5 cm by palpation or on imaging.

4. Histologic Bloom Richardson grade ≥2.

4. Invasive ductal or lobular carcinoma, invasive carcinoma Not Otherwise Specified (NOS).

5. ECOG PS 0-2 (Appendix A). 6. The participant (or legally acceptable representative if applicable) is able to provide written informed consent for the study.

Exclusion Criteria

1. Locally advanced or metastatic breast cancer.

2. Prior therapy with chemotherapy or planned neoadjuvant chemotherapy.

3. Pre-dominant histology other than invasive ductal or lobular carcinoma or invasive carcinoma NOS.

4. Patients with an active infection.

5. Absolute Neutrophil Count < 1.5 x 10^9/L.

6. Patients with pre-existing renal impairment, Creatinine clearance calculated by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation of less than 50 mL/min/1.73m2.

7. Any serious known immediate or delayed hypersensitivity reaction(s) to vinblastine or cisplatin or idiosyncrasy to drugs chemically related to the investigational drugs.

8. Known allergic reaction to local anesthetic (Xylocaine, Marcaine).

9. Concurrent medical condition requiring the use of immunosuppressive medications, or systemic corticosteroids at doses of greater than 10 mg Prednisone-equivalent Topical steroids and other localized corticosteroids are permitted. Use of steroids as prophylactic treatment for subjects with contrast allergies to diagnostic imaging contrast dyes will be permitted.

10. Concurrent use of a prohibited medication or planned use of any forbidden medications during treatment with INT230-6, or within 4 weeks prior to study drug administration, which include chemotherapy, immunotherapy (tumor vaccine, cytokine, or growth factor given to control the cancer: systemic or intratumoral), other biologic therapy, investigational therapy, or hormonal therapy, cisplatin containing agents, and vinblastine containing agents while on treatment in this study. Other prohibited concomitant medications that will interact with vinblastine and cisplatin include mitomycin, phenytoin, CYP3A4 inhibitors (ketoconazole, voriconazole, clarithromycin, erythromycin), nephrotoxic drugs (aminoglycosides, amphotericin), or pure pyridoxine (pyridoxine contained in multivitamin is permitted). Use of other investigational drugs (drugs not marketed for any indication) within 4 weeks prior to study drug administration not permitted.

11. Pregnancy if patient is of childbearing age) or breast feeding.

12. Subjects with signs/symptoms suggestive of COVID-19 or known COVID-19 positive contacts in the past 14 days would be tested as per local Public Health and/or Institutional Guidelines. If patients are COVID-19 positive at the time of screening, they would be excluded from the trial.

13. Any underlying medical condition that, in the Principal Investigator's opinion, will make the administration of study drug hazardous or obscure the interpretation of toxicity determination or adverse events, or renders the patient ineligible to be on study.

• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Intensity Therapeutics, Inc.

INDUSTRY

Sponsor Role: collaborator

Ontario Institute for Cancer Research

OTHER

Sponsor Role: collaborator

Ottawa Hospital Research Institute

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Angel Arnaout, MD

Role: PRINCIPAL_INVESTIGATOR

Ottawa Hospital Research Institute

Arif Awan, MD

Role: PRINCIPAL_INVESTIGATOR

Ottawa Hospital Research Institute

Locations

The Ottawa Hospital Research Institute and Cancer Center

Ottawa, Ontario, Canada

Site Status: RECRUITING

Countries

Canada

Central Contacts

Angel Arnaout, MD

Role: CONTACT

Phone: 6137985555

Email: anarnaout@toh.on.ca

Facility Contacts

Angel Arnaout, MD

Role: primary

Other Identifiers

OTT 20-11 (IT-02)

Identifier Type: -

Identifier Source: org_study_id